← Leaderboards

Terence R. Flotte

University Of Florida

Google Scholar ↗PubMed ↗ORCID ↗

$26,412,339

Attributed

$27,328,042

Total exposure

27

Grants

18

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.7M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$62,031,222 · 31

By mechanism

P01$42,155,211 · 13

U42$6,711,904 · 4

R01$6,551,045 · 2

G20$5,237,334 · 1

M01$883,093 · 9

P50$489,442 · 1

Top collaborators

Christian Mueller5 shared

Most similar at University Of Florida

Same institution · by research overlap

Saad Sammani$1,090,292
Michael Shane Stalvey$602,424

Others in their field

Top investigators on “Gene Therapy”

David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
Randall J Bateman · Washington University$122,781,098
Eric Martin McDade · Washington University$94,632,845
Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
Robert B. Diasio · University Of Alabama At Birmingham$73,470,685

Research focus

Gene TherapyAlpha 1-Antitrypsin DeficiencyVectorGenesLung DiseasesCapsidMediatingLaboratoriesAlpha 1-AntitrypsinRecombinant Adeno-Associated Virus (Raav)LiverProgramsSerumResponseProteinsPulmonary EmphysemaClinical TrialsAdeno Associated Virus GroupResearch PersonnelNonhuman PrimateBasePhenotypeSerotypingLead

Grant awards (100)

Models and Gene Therapies for AAT Deficiency$2,728,017

P01 · FY2025 · HL · contact PI

Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models$419,278

P01 · FY2025 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$83,749

P01 · FY2025 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$2,673,457

P01 · FY2024 · HL · contact PI

Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models$411,484

P01 · FY2024 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$75,954

P01 · FY2024 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$2,728,017

P01 · FY2023 · HL · contact PI

Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models$419,278

P01 · FY2023 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$83,749

P01 · FY2023 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$2,676,698

P01 · FY2022 · HL · contact PI

Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models$432,198

P01 · FY2022 · HL · contact PI

Nuclease free gene editing approaches to treat alpha-1 antitrypsin disease$376,875

R01 · FY2022 · DK · contact PI

Models and Gene Therapies for AAT Deficiency$83,750

P01 · FY2022 · HL · contact PI

Models and Gene Therapies for AAT Deficiency$2,789,128

P01 · FY2021 · HL · contact PI

Optimized Gene Replacement for AAT deficiency and Modeling of Clinical Outcomes in small and large animal models$544,628

P01 · FY2021 · HL · contact PI

Nuclease free gene editing approaches to treat alpha-1 antitrypsin disease$376,875

R01 · FY2021 · DK · contact PI

Models and Gene Therapies for AAT Deficiency$83,750

P01 · FY2021 · HL · contact PI

New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency$2,339,301

P01 · FY2020 · HL · contact PI

Clinical Trial and Immunologic aspects of muscle-directed rAAV1-AAT gene therapy$502,500

P01 · FY2020 · HL · contact PI

Nuclease free gene editing approaches to treat alpha-1 antitrypsin disease$376,875

R01 · FY2020 · DK · contact PI

Administrative Core$49,395

P01 · FY2020 · HL · contact PI

New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency$2,335,926

P01 · FY2019 · HL · contact PI

Clinical Trial and Immunologic aspects of muscle-directed rAAV1-AAT gene therapy$502,500

P01 · FY2019 · HL · contact PI

Nuclease free gene editing approaches to treat alpha-1 antitrypsin disease$376,875

R01 · FY2019 · DK

Administrative Core$49,395

P01 · FY2019 · HL · contact PI

New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency$2,346,142

P01 · FY2018 · HL · contact PI

Clinical Trial and Immunologic aspects of muscle-directed rAAV1-AAT gene therapy$477,375

P01 · FY2018 · HL · contact PI

Administrative Core$44,423

P01 · FY2018 · HL · contact PI

New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency$2,064,892

P01 · FY2017 · HL · contact PI

Clinical Trial and Immunologic aspects of muscle-directed rAAV1-AAT gene therapy$477,375

P01 · FY2017 · HL · contact PI

Administrative Core$44,423

P01 · FY2017 · HL · contact PI

New Approaches to Gene Therapy for Alpha-1 Antitrypsin Deficiency$2,252,833

P01 · FY2016 · HL · contact PI

Clinical Trial and Immunologic aspects of muscle-directed rAAV1-AAT gene therapy$502,500

P01 · FY2016 · HL · contact PI

Dual-function vectors for in vivo gene therapy of AAT Liver disease$364,313

R01 · FY2016 · DK · contact PI

Administrative Core$49,394

P01 · FY2016 · HL · contact PI

Dual-function vectors for in vivo gene therapy of AAT Liver disease$364,313

R01 · FY2015 · DK · contact PI

Dual-function vectors for in vivo gene therapy of AAT Liver disease$363,950

R01 · FY2014 · DK · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$384,619

R01 · FY2013 · HL · contact PI

Dual-function vectors for in vivo gene therapy of AAT Liver disease$361,956

R01 · FY2013 · DK · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$404,011

R01 · FY2012 · HL · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$408,092

R01 · FY2011 · HL · contact PI

UMass BSL-3 Renovation$5,237,334

G20 · FY2010 · RR · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$408,092

R01 · FY2010 · HL · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$406,867

R01 · FY2009 · HL · contact PI

Liver-directed Gene Therapy for Alpha 1 Antitrypsin (AAT) Deficiency$269,702

P01 · FY2009 · DK · contact PI

Expression System with Adeno-Associated Viral Vectors$437,949

P01 · FY2008 · HL · contact PI

Liver-directed Gene Therapy for Alpha 1 Antitrypsin (AAT) Deficiency$253,222

P01 · FY2008 · DK · contact PI

Expression System with Adeno-Associated Viral Vectors$438,006

P01 · FY2007 · HL · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$256,374

R01 · FY2007 · HL · contact PI

PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF A RECOMBINANT ADENO-ASSOCIATED VIRUS$53,600

M01 · FY2007 · RR · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$19,546

R01 · FY2007 · HL · contact PI

L2762G EFF OF NUTROPIN AQ FOR TRMT OF GROWTH RESTRICTION IN CHILD W CF$13,937

M01 · FY2007 · RR · contact PI

PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF A RECOMBINANT ADENO-ASSOCIATED VIRUS$10,721

M01 · FY2007 · RR · contact PI

Recombinant AAV for Correction of Genetic Abnormalities$1,259,543

P01 · FY2006 · DK · contact PI

ESTABLISHMENT OF NGVL TOXICOLOGY LAB: RAAV VECTORS, CYSTIC FIBROSIS$349,184

U42 · FY2006 · RR · contact PI

Expression System with Adeno-Associated Viral Vectors$304,465

P01 · FY2006 · HL · contact PI

Preclinical & Phase I/II Trials of AAV-AAT Vectors$284,162

R01 · FY2006 · HL · contact PI

AAV vector delivery to skeletal muscle, platform for therapeutic protein delivery$219,976

P01 · FY2006 · HL · contact PI

Liver-directed Gene Therapy for Alpha 1 Antitrypsin (AAT) Deficiency$193,134

P01 · FY2006 · DK · contact PI

PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF A RECOMBINANT ADENO-ASSOCIATED VIRUS$132,696

M01 · FY2006 · RR · contact PI

L2762G EFF OF NUTROPIN AQ FOR TRMT OF GROWTH RESTRICTION IN CHILD W CF$10,562

M01 · FY2006 · RR · contact PI

ESTABLISHMENT OF NGVL TOXICOLOGY LAB: RAAV VECTORS, CYSTIC FIBROSIS$2,937,964

U42 · FY2005 · RR

Recombinant AAV for Correction of Genetic Abnormalities$1,277,583

P01 · FY2005 · DK

AAV vector delivery to skeletal muscle, platform for therapeutic protein delivery$383,833

P01 · FY2005 · HL

Expression System with Adeno-Associated Viral Vectors$298,521

P01 · FY2005 · HL

Preclinical &Phase I/II Trials of AAV-AAT Vectors$291,000

R01 · FY2005 · HL

Liver-directed Gene Therapy for Alpha 1 Antitrypsin (AAT) Deficiency$205,974

P01 · FY2005 · DK

Preclinical &Phase I/II Trials Of AAV-AAT Vectors$145,500

R01 · FY2005 · HL

PHASE I TRIAL OF INTRAMUSCULAR INJECTION OF A RECOMBINANT ADENO-ASSOCIATED VIRUS$113,689

M01 · FY2005 · RR

Administrative Core$21,666

P01 · FY2005 · DK

ESTABLISHMENT OF NGVL TOXICOLOGY LAB: RAAV VECTORS, CYSTIC FIBROSIS$1,158,580

U42 · FY2004 · RR

NGVL TOXICOLOGY LABORATORY$1,158,580

U42 · FY2004 · RR

RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES$1,051,117

P01 · FY2004 · DK

Expression System with Adeno-Associated Viral Vectors$301,284

P01 · FY2004 · HL

Preclinical &Phase I/II Trials of AAV-AAT Vectors$290,750

R01 · FY2004 · HL

Molecular Therapies for A1A Liver Disease. Sub: Estab Cell Lines for Lab Inv$803

M01 · FY2004 · RR

RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES$1,021,143

P01 · FY2003 · DK

NGVL TOXICOLOGY LABORATORY$334,695

U42 · FY2003 · RR

Preclinical &Phase I/II Trials of AAV-AAT Vectors$290,000

R01 · FY2003 · HL

NGVL TOXICOLOGY LABORATORY$3,193

P51 · FY2003 · RR

RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES$992,040

P01 · FY2002 · DK

NGVL TOXICOLOGY LABORATORY$439,135

U42 · FY2002 · RR

AAV vector delivery to skeletal muscle, platform for therapeutic protein delivery$219,976

P01 · FY2002 · HL

GENE THERAPY FOR LIVER AND LUNG DISEASE$187,476

P01 · FY2002 · DK

ADENO-ASSOCIATED VIRUS VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$0

P01 · FY2002 · HL

RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES$963,786

P01 · FY2001 · DK

NGVL TOXICOLOGY LABORATORY$333,766

U42 · FY2001 · RR

AAV VECTOR DELIVERY TO SKELETAL MUSCLE--THERAPEUTIC PROTEIN DELIVERY PLATFORM$219,976

P50 · FY2001 · HL

PHASE I STUDY--ADENO ASSOCIATED VIRUS CFTR GENE VECTOR IN ADULT CYSTIC FIBROSIS$207,281

M01 · FY2001 · RR

GENE THERAPY FOR LIVER AND LUNG DISEASE$187,476

P01 · FY2001 · DK

PHASE I STUDY--ADENO ASSOCIATED VIRUS CFTR GENE VECTOR IN ADULT CYSTIC FIBROSIS$55,741

M01 · FY2001 · RR

ADENO-ASSOCIATED VIRUS VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$0

P01 · FY2001 · HL

RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES$937,381

P01 · FY2000 · DK

ADENO-ASSOCIATED VIRUS VECTORS FOR CYSTIC FIBROSIS GENE THERAPY$270,973

P01 · FY2000 · HL

AAV VECTOR DELIVERY TO SKELETAL MUSCLE--THERAPEUTIC PROTEIN DELIVERY PLATFORM$269,466

P50 · FY2000 · HL

EFFECTS OF NICOTINE NASAL SPRAY DEVICE ON CARDIOVASCULAR &PULMONARY$207,281

M01 · FY2000 · RR

GENE THERAPY FOR LIVER AND LUNG DISEASE$187,476

P01 · FY2000 · DK

PHASE I STUDY--ADENO ASSOCIATED VIRUS CFTR GENE VECTOR IN ADULT CYSTIC FIBROSIS$38,391

M01 · FY2000 · RR

EFFECTS OF NICOTINE NASAL SPRAY DEVICE ON CARDIOVASCULAR &PULMONARY$38,391

M01 · FY2000 · RR

PHASE I STUDY--ADENO ASSOCIATED VIRUS CFTR GENE VECTOR IN ADULT CYSTIC FIBROSIS$0

M01 · FY2000 · RR